Topical review on the abuse and misuse potential of tramadol and tilidine in Germany

Substance Abuse

Volumn 34, Issue 3, 2013, Pages 313-320

  Radbruch, Lukas ^a,b   Glaeske, Gerd ^b   Grond, Stefan ^c   Münchberg, Frank ^d   Scherbaum, Norbert ^e   Storz, Elisabeth ^f   Tholen, Kathrin ^b   Zagermann Muncke, Petra ^g   Zieglgänsberger, Walter ^h   Hoffmann Menzel, Helmut ^b   Greve, Hendrik ⁱ   Cremer Schaeffer, Peter ^i,j  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c Lippe Detmold Hospital   (Germany)

^d German Med Manufacturers' Assoc   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f VFA DIE FORSCHENDEN PHARMA UNTERNEHMEN   (Germany)

^g Drug Commission of German Pharmacists   (Germany)

^h MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

ⁱ Malteser Hospital Bonn   (Germany)

^j FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

more..

Author keywords

abuse and misuse potential; prescription fraud; prescription patterns; tilidine; Tramadol

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT; TILIDINE; TRAMADOL;

DRUG COMBINATION; FRAUD; GERMANY; HUMAN; INCIDENCE; OPIATE ADDICTION; PAIN; REVIEW; SELF MEDICATION; STATISTICS;

ANALGESICS, OPIOID; DRUG THERAPY, COMBINATION; FRAUD; GERMANY; HUMANS; INCIDENCE; NALOXONE; OPIOID-RELATED DISORDERS; PAIN; SELF MEDICATION; TILIDINE; TRAMADOL;

EID: 84880294141     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2012.735216     Document Type: Review

References (43)

1. World Health Organization. 1996. Cancer Pain Relief: With a Guide to Opioid Availability,. 2. ed, Geneva, World Health Organization
2. World Health Organization. 1986. Cancer Pain Relief, Geneva: World Health Organization.
3. International Narcotic Control Board. 2011. Narcotic Drugs-Estimated World Requirements for 2011, Statistics for 2009, New York: United Nations.
4. Coller, J K, Christrup, L L, and, Somogyi, A A. 2009. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol, 65: 121-139.
5. Schulz, M, and, Schmoldt, A. 2003. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie, 58: 447-474. (Pubitemid 36869876)
6. Grond, S, and, Sablotzki, A. 2004. Clinical pharmacology of tramadol. Clin Pharmacokinet, 43: 879-923. (Pubitemid 39447033)
7. Raffa, R B, and, Stone, D J Jr. 2008. Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice. J Pharmacol Exp Ther, 325: 500-506. (Pubitemid 351574810)
8. Wustrow, I, Riedel, K D, Mikus, G, and, Weiss, J. 2012. In vitro identification of the cytochrome P450 isozymes involved in the N-demethylation of the active opioid metabolite nortilidine to bisnortilidine. Naunyn Schmiedebergs Arch Pharmacol, 385: 633-639.
9. Bundesministerium für Justiz. 2011. Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz, BtMG).
10. Bundesministerium für Justiz. 2011. Verordnung über das Verschreiben, die Abgabe und den Nachweis des Verbleibs von Betä ubungsmitteln (Betäubungsmittel-Verschreibungsverordnung, BtMVV).
11. Caulkins, J P, Reuter, P, and, Coulson, C. 2011. Basing drug scheduling decisions on scientific ranking of harmfulness: false promise from false premises. Addiction, 106: 1886-1890.
12. Schwabe, U, and, Paffrath, D. 2010. Arzneiverordnungs-Report 2010, Berlin: Springer Verlag.
13. IMS Health. 2010. DPM-Der Pharmazeutische Markt Deutschland. Statistik über Human-Arzneimittel-Einkäufe öffentlicher Apotheken, Frankfurt am Main: IMS Health.
14. WHO Collaborating Centre for Drug Statistics Methodology. 2010. ATC/DDD Index 2011. Available at: http://www.whocc.no/atc-ddd-index./Accessed November 5, 2011
15. Radbruch, L, Grond, S, and, Lehmann, K A. 1996. A risk-benefit assessment of tramadol in the management of pain. Drug Saf., 15: 3-23.
16. Hollingshead, J, Duhmke, R M, and, Cornblath, D R. 2006. Tramadol for neuropathic pain. Cochrane Database Syst Rev,. CD003726
17. Deutsche Interdisziplinäre Vereinigung für Schmerztherapie. 2009. AWMF S3-Leitlinie Akutschmerz. Available at: http://www.awmf.org/ leitlinien/detail/ll/041-001.html. Accessed November 5, 2011
18. Arzneimittelkommission der Deutschen Ärzteschaft. 2007. Empfehlungen zur Therapie von Tumorschmerzen. Arzneiverordnung in der Praxis,: 3. Auflage
19. Macintyre PE, Schug SA, Scott DA, Visser EJ, Walker SM; APM: SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. 2010. Acute Pain Management: Scientific Evidence 3rd ed., Melbourne, Australia: ANZCA & FPM. Available at: http://www.anzca.edu.au/ resources/books-and-publications. Accessed November 5, 2011
20. Reinecke, H, and, Sorgatz, H. 2009. [S3 guideline LONTS. Long-term administration of opioids for non-tumor pain]. Schmerz, 23: 440-447.
21. Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft Wissenschaftlich-Medizinischer Fachgesellschaften. 2010. Nationale VersorgungsLeitlinie Kreuzschmerz. Available at: http://www.awmf.org/ leitlinien/detail/ll/nvl-007.html. Accessed November 5, 2011
22. Raffa, R B. 2008. Basic pharmacology relevant to drug abuse assessment: tramadol as example. J Clin Pharm Ther., 33: 101-108. (Pubitemid 351341408)
23. Duke, A N, Bigelow, G E, Lanier, R K, and, Strain, E C. 2011. Discriminative stimulus effects of tramadol in humans. J Pharmacol Exp Ther., 338: 255-262.
24. Lanier, R K, Lofwall, M R, Mintzer, M Z, Bigelow, G E, and, Strain, E C. 2010. Physical dependence potential of daily tramadol dosing in humans. Psychopharmacology (Berl)., 211: 457-466.
25. Epstein, D H, Preston, K L, and, Jasinski, D R. 2006. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychol., 73: 90-99.
26. Trojan, A, and, Beil, H W. 1978. Tilidine abuse and dependence. Drug Alcohol Depend., 3: 383-391. (Pubitemid 9088054)
27. Jasinski, D R, and, Preston, K L. 1986. Evaluation of tilidine for morphine-like subjective effects and euphoria. Drug Alcohol Depend., 18: 273-292. (Pubitemid 17219239)
28. Preston, K L, Jasinski, D R, and, Testa, M. 1991. Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend., 27: 7-17.
29. Adams, E H, Breiner, S, Cicero, T J. 2006. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage., 31: 465-476. (Pubitemid 43744403)
30. Roider, G, Dasch, G, van Meyer, L, and, Sachs, H. 2000. Tramadol als Drogenersatz. Deutsche Apotheker Zeitung., 140: 55-58.
31. Grünenthal. 2010. Scientific Evaluation of the Abuse Situation of Tramadol Containing Medicinal Products, Stolberg: Grünenthal.
32. Uppsala Monitoring Centre. 2011. Vigibase Services. Available at: http://www.umc-products.com/DynPage.aspx?id=4910&mn=1107. Accessed November 6, 2011
33. Lachmann, N, Nolting, A, and, Stuhr, T. 2011. Bericht über das gemeinschaftliche Drug-Monitoring Tilidin/Naloxon-haltiger Arzneimittel für das Jahr 2010, Berlin: Pfizer.
34. Spiller, H A, Scaglione, J M, Aleguas, A. 2010. Effect of scheduling tramadol as a controlled substance on poison center exposures to tramadol. Ann Pharmacother., 44: 1016-1021.
35. Marquardt, K A, Alsop, J A, and, Albertson, T E. 2005. Tramadol exposures reported to statewide poison control system. Ann Pharmacother., 39: 1039-1044. (Pubitemid 40695970)
36. De Decker, K, Cordonnier, J, Jacobs, W, Coucke, V, Schepens, P, and, Jorens, P G. 2008. Fatal intoxication due to tramadol alone: case report and review of the literature. Forensic Sci Int., 175: 79-82. (Pubitemid 351172649)
37. De Backer, B, Renardy, F, Denooz, R, and, Charlier, C. 2010. Quantification in postmortem blood and identification in urine of tramadol and its two main metabolites in two cases of lethal tramadol intoxication. J Anal Toxicol., 34: 599-604.
38. Kraus, L, and, Pabst, A. 2010. Studiendesign und Methodik des epidemiologischen Suchtsurveys 2009. Sucht., 56: 315-326.
39. Küfner, H, and, Rösner, S. 2008. Monitoring des Arzneimittelmissbrauchs bei Klienten ambu-lanter Suchtberatungsstellen (PHAR-MON). Gesundheitswesen., 70: 305-314.
40. Jaffe, J H. 1985. Impact of scheduling on the practice of medicine and biomedical research. Drug Alcohol Depend., 14: 403-418. (Pubitemid 15149060)
41. Hellerstein, D J, and, Biedermann, G B. 2003. Physician concerns with United States Drug Enforcement Agency Schedule II central nervous system stimulants. Primary Psychiatry., 10: 47-52. (Pubitemid 38436116)
42. World Health Organization. 2011. Ensuring Balance in National Policies on Controlled Substances-Guidance for Availability and Accessibility of Controlled Medicines, Geneva: WHO Press.
43. World Health Organization. 2006. WHO Expert Committee on Drug Dependence, 34th Meeting. World Health Organ Tech Rep Ser 942., i: 23-24. 1-21, Geneva, passim